Literature DB >> 16888412

CD10 expression in urothelial bladder carcinomas: a pilot study.

Sema Bircan1, Ozden Candir, Nilgun Kapucuoglu, T Ahmet Serel, Metin Ciris, Nermin Karahan.   

Abstract

OBJECTIVES: The aims of this study were to investigate the expression of CD10 in normal bladder tissue and urothelial bladder carcinomas and to clarify its association with histopathological variables.
MATERIALS AND METHODS: A total of 79 urothelial bladder carcinomas were selected from routine archival material. All cases were reevaluated histopathologically and graded according to the World Health Organization (WHO) 1973, WHO/ISUP 1998, and WHO 1999 systems. The TNM system was used for their pathological staging. CD10 immunohistochemical staining was performed in selected slides.
RESULTS: Tumoral cases consisted of 74 men (93.7%) and 5 women (6.3%). According to the pathological stage, 25 (31.6%), 33 (41.8%), and 21 (26.6%) cases had pTa, pT1, and pT2-3 carcinomas, respectively. 34 of 79 (43%) urothelial carcinomas and only 1 of 11 (9.1%) nontumoral cases showed positive CD10 immunostaining. It was a cytoplasmic diffuse or granular immunostaining pattern both in nontumoral and tumoral urothelia. There was no statistically significant difference between tumoral and nontumoral cases with respect to CD10 reactivity (p = 0.051), but there was a trend toward significance. In urothelial tumors, there was a significant inverse correlation between pathological stages and CD10 immunoreactivity (p = 0.036, r = -0,237). There was also a statistically significant difference between pTa and pT2-3 urothelial tumors in relation to the CD10 expression (p = 0.034). No association was detected between CD10 expression and grades according to all systems used (p > 0.05).
CONCLUSIONS: According to our findings, the CD10 expression in noninvasive carcinomas showed a higher level than that in invasive carcinomas, and it is inversely correlated with the pathological stage. CD10 may play an important role in the progression of urothelial bladder carcinomas, and downregulation probably facilitates invasion, especially muscle invasion.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16888412     DOI: 10.1159/000093901

Source DB:  PubMed          Journal:  Urol Int        ISSN: 0042-1138            Impact factor:   2.089


  7 in total

1.  An Optimized Evans Blue Protocol to Assess Vascular Leak in the Mouse.

Authors:  Marilee J Wick; Julie W Harral; Zoe L Loomis; Edward C Dempsey
Journal:  J Vis Exp       Date:  2018-09-12       Impact factor: 1.355

2.  CD10 Is Again Expressed at a Certain Stage during the Neoplastic Process of Bladder Transitional Cell Carcinomas.

Authors:  Tae Jung Jang
Journal:  Cancer Res Treat       Date:  2012-12-31       Impact factor: 4.679

3.  Synergistic relationship between dipeptidyl peptidase IV and neutral endopeptidase expression and the combined prognostic significance in osteosarcoma patients.

Authors:  Hongtao Zhang; Haibin Lin; Xiaoqiong Mo; Guoli Chen; Lijun Lin
Journal:  Med Oncol       Date:  2013-05-18       Impact factor: 3.064

4.  Expression and Regulatory Network Analysis of MiR-139-3p, a New Potential Serum Biomarker for Esophageal Squamous Cell Carcinoma Based on Bioinformatics Analysis.

Authors:  Yonghong Wang; Qimei Fang; Liru Tian; Zhongzhen Yuan; Lizhen Tian; Zhongli Zhou
Journal:  Technol Cancer Res Treat       Date:  2020 Jan-Dec

5.  The circulating form of neprilysin is not a general biomarker for overall survival in treatment-naïve cancer patients.

Authors:  Noemi Pavo; Henrike Arfsten; Anna Cho; Georg Goliasch; Philipp E Bartko; Raphael Wurm; Claudia Freitag; Heinz Gisslinger; Gabriela Kornek; Guido Strunk; Markus Raderer; Christoph Zielinski; Martin Hülsmann
Journal:  Sci Rep       Date:  2019-02-22       Impact factor: 4.379

6.  Assessing CD 10 Expression Level and Its Prognostic Impact in Egyptian Patients with Urothelial Carcinoma.

Authors:  Marwa T Hussien; Eatemad Helmy; Tarek M Elsaba; Azza Elkady; Hani Alrefai; Helal F Hetta
Journal:  Asian Pac J Cancer Prev       Date:  2020-06-01

7.  CD10 expression in urothelial carcinoma of the bladder.

Authors:  Burak Bahadir; Kemal Behzatoglu; Sibel Bektas; Erol R Bozkurt; Sukru O Ozdamar
Journal:  Diagn Pathol       Date:  2009-11-16       Impact factor: 2.644

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.